LINC01133

Summary

LINC01133 (long intergenic non-protein coding RNA 1133, HGNC:49447) is a long non-coding RNA gene on chromosome 1q23.2.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:49447
Approved symbol	LINC01133
Name	long intergenic non-protein coding RNA 1133
Location	1q23.2
Locus type	RNA, long non-coding
Status	Approved
Aliases	lncRNA-PAGBC
Ensembl gene	ENSG00000224259
Ensembl biotype	lncRNA
Entrez	100505633
RNAcentral	URS000075A942 — lncRNA, 1154 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 30 lncRNA

ENST00000423943, ENST00000443364, ENST00000635112, ENST00000657602, ENST00000701616, ENST00000772280, ENST00000772281, ENST00000772282, ENST00000772283, ENST00000772284, ENST00000772285, ENST00000772286, ENST00000772287, ENST00000772288, ENST00000772289, ENST00000772290, ENST00000772292, ENST00000772294, ENST00000772296, ENST00000772297, ENST00000772299, ENST00000772301, ENST00000772302, ENST00000772303, ENST00000772304, ENST00000772305, ENST00000772306, ENST00000772307, ENST00000772308, ENST00000772309

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000423943 — 3 exons

Exon	Start	End
ENSE00001751381	159976644	159977112
ENSE00004136081	159961078	159961405
ENSE00004136096	159978600	159979280

Expression profiles

Bgee: expression breadth ubiquitous, 181 present calls, max score 96.46.

FANTOM5 (CAGE): breadth broad, TPM avg 6.5899 / max 576.1547, expressed in 583 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6028	6.1078	578
6030	0.3268	113
6027	0.0980	51
6029	0.0573	24

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	96.46	gold quality
jejunal mucosa	UBERON:0000399	95.09	gold quality
mucosa of transverse colon	UBERON:0004991	93.79	gold quality
duodenum	UBERON:0002114	89.72	gold quality
colonic mucosa	UBERON:0000317	89.37	gold quality
rectum	UBERON:0001052	89.14	gold quality
right uterine tube	UBERON:0001302	87.66	gold quality
mucosa of sigmoid colon	UBERON:0004993	87.09	gold quality
germinal epithelium of ovary	UBERON:0001304	85.10	gold quality
epithelial cell of pancreas	CL:0000083	84.53	gold quality
lower esophagus mucosa	UBERON:0035834	83.75	gold quality
transverse colon	UBERON:0001157	83.06	gold quality
small intestine	UBERON:0002108	83.05	gold quality
esophagus mucosa	UBERON:0002469	82.58	gold quality
small intestine Peyer’s patch	UBERON:0003454	82.38	gold quality
skin of abdomen	UBERON:0001416	81.62	gold quality
minor salivary gland	UBERON:0001830	81.44	gold quality
sural nerve	UBERON:0015488	81.02	gold quality
body of stomach	UBERON:0001161	80.99	gold quality
skin of leg	UBERON:0001511	80.48	gold quality
zone of skin	UBERON:0000014	80.45	gold quality
colonic epithelium	UBERON:0000397	80.12	gold quality
mouth mucosa	UBERON:0003729	80.05	gold quality
stomach	UBERON:0000945	79.54	gold quality
intestine	UBERON:0000160	78.49	gold quality
parietal pleura	UBERON:0002400	78.48	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	78.08	gold quality
palpebral conjunctiva	UBERON:0001812	77.99	gold quality
mucosa of stomach	UBERON:0001199	77.88	gold quality
vagina	UBERON:0000996	77.48	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.90

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 32)

• LINC01133 is upregulated in lung squamous cell cancer. (PMID:25908174)
• Authors found that there was negative correlation between LINC01133 and KLF2, P21 or E-cadherin in NSCLC. (PMID:26840083)
• LINC01133 inhibits epithelial mesenchymal transformation and metastasis in colorectal neoplasms by directly binding to SRSF6 as a target mimic. (PMID:27443606)
• Our results indicated that reduced LINC01133 expression contributed to colorectal cancer metastasis and poor prognosis (PMID:28537675)
• study identifies a group of differentially expressed lncRNAs in human gallbladder cancer (GBC) tissues, including prognosis-associated gallbladder cancer lncRNA (lncRNA-PAGBC), which was found to be an independent prognostic marker in GBC. Functional analysis indicates lncRNA-PAGBC promotes tumour growth and metastasis of GBC cells (PMID:28887321)
• our findings revealed that the C/EBPbeta-LINC01133 axis performs an oncogenic function in pancreatic ductal adenocarcinoma by activating CCNG1 (PMID:29458145)
• Findings suggest that reduced expression of LINC01133 is associated with aggressive tumor phenotypes and poor patient outcomes in gastric cancer (GC). LINC01133 inhibits GC progression and metastasis by acting as a ceRNA for miR-106a to regulate APC expression and the Wnt/beta-catenin pathway, suggesting that LINC01133 may serve as a potential prognostic biomarker. (PMID:30134915)
• Data indicate that LINC01133 inhibited OSCC metastasis via a feedback regulation loop of reciprocal inhibition with GDF15. (PMID:30332510)
• tissue-specific down-regulation of PCAT18 and LINC01133 in gastric and other gastrointestinal cancers imply that these long noncoding RNAs may have a tumor suppressive function in the development of these tumor entities. (PMID:30518158)
• The knockdown of LINC01133 dramatically repressed hepatocellular carcinoma tumor progression through targeting the PI3K/AKT pathway in vivo. (PMID:30548306)
• Study clarified the distinct effect of LINC01133 on pancreatic cancer. In summary, by inducing the methylation of DKK1 promoter, LINC01133 silencing suppresses the development of pancreatic cancer cells through the Wnt signaling pathway. (PMID:30580676)
• Authors establish that LINC01133 is sufficient, on its own, in promoting phenotypic and growth characteristics of cancer stem cell-like cells, and that it is a direct mediator of the MSC-triggered miR-199a-FOXP2 pathway in TNBC models. (PMID:31283068)
• we unveiled that LINC01133 may function as a ceRNA for miR-4784 to advance AHDC1 expression, intensifying CC cell malignant phenotypes and EMT process, which may demonstrate the implied value of LINC01133 as a therapeutic target for CC patients. (PMID:31390932)
• Because of its role as an miR-205 sponge, LINC01133 repressed the development of ovarian cancer by up-regulating LRRK2. (PMID:31640854)
• Hydrostatic pressure induces osteogenic differentiation of adipose-derived mesenchymal stem cells through increasing lncRNA-PAGBC. (PMID:32661199)
• MiR-216a-5p inhibits tumorigenesis in Pancreatic Cancer by targeting TPT1/mTORC1 and is mediated by LINC01133. (PMID:32792860)
• LINC01133 contribute to epithelial ovarian cancer metastasis by regulating miR-495-3p/TPD52 axis. (PMID:33036757)
• Sevoflurane protects cardiomyocytes against hypoxia/reperfusion injury via LINC01133/miR-30a-5p axis. (PMID:33175096)
• Exosomes-mediated transfer of long noncoding RNA LINC01133 represses bladder cancer progression via regulating the Wnt signaling pathway. (PMID:33728699)
• Tumor-derived exosomal long noncoding RNA LINC01133, regulated by Periostin, contributes to pancreatic ductal adenocarcinoma epithelial-mesenchymal transition through the Wnt/beta-catenin pathway by silencing AXIN2. (PMID:33824474)
• LINC01133 promotes hepatocellular carcinoma progression by sponging miR-199a-5p and activating annexin A2. (PMID:34047479)
• LINC01133 hampers the development of gastric cancer through increasing somatostatin via binding to microRNA-576-5p. (PMID:34318683)
• LINC01133 Inhibits Invasion and Promotes Proliferation in an Endometriosis Epithelial Cell Line. (PMID:34445100)
• Linc01133 contributes to gastric cancer growth by enhancing YES1-dependent YAP1 nuclear translocation via sponging miR-145-5p. (PMID:35017464)
• Clinical potential of long non-coding RNA LINC01133 as a promising biomarker and therapeutic target in cancers. (PMID:35195032)
• Linc01133 promotes proliferation and metastasis of human renal cell carcinoma through sponging miR-760. (PMID:35446199)
• Role of LINC01133 in Osteogenic Differentiation of Dental Pulp Stem Cells by Targeting miR-199b-5p. (PMID:35481341)
• [Long non-coding RNA LINC01133 regulates cementogenic differentiation of human periodontal ligament stem cells by modulating mitochondrial functions]. (PMID:36509520)
• A novel pyroptosis-associated lncRNA LINC01133 promotes pancreatic adenocarcinoma development via miR-30b-5p/SIRT1 axis. (PMID:37138146)
• LINC01133 can induce acquired ferroptosis resistance by enhancing the FSP1 mRNA stability through forming the LINC01133-FUS-FSP1 complex. (PMID:38007473)
• LINC01133 contributes to the malignant phenotypes of non-small cell lung cancer by targeting miR-30b-5p/FOXA1 pathway. (PMID:38836682)
• LINC01133 promotes pancreatic ductal adenocarcinoma epithelial-mesenchymal transition mediated by SPP1 through binding to Arp3. (PMID:38987572)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.